{"transactions":[{"id":4616059,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":29578,"kind":"person","name":"Sibold William John","position":1,"cik":"0001518611","reported_name":"Sibold William John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-09-11T20:57:12.000Z","date":"2026-09-11","kind":"sale","planned":true,"acquired":false,"shares":120,"price":546.3767,"value":65565.204,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F16","text":"These sales were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F26","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $546.28 to $546.56, inclusive."}],"balance_after":197746,"source":{"system":"sec-edgar","filing":"0001628280-26-061581","document":"wk-form4_1789160228.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":24,"url":"https://www.sec.gov/Archives/edgar/data/1518611/000162828026061581/wk-form4_1789160228.xml","form_type":"4"}},{"id":4616058,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":29578,"kind":"person","name":"Sibold William John","position":1,"cik":"0001518611","reported_name":"Sibold William John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-09-11T20:57:12.000Z","date":"2026-09-11","kind":"sale","planned":true,"acquired":false,"shares":761,"price":544.8307,"value":414616.1627,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F16","text":"These sales were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F25","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $544.38 to $545.32, inclusive."}],"balance_after":197866,"source":{"system":"sec-edgar","filing":"0001628280-26-061581","document":"wk-form4_1789160228.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/1518611/000162828026061581/wk-form4_1789160228.xml","form_type":"4"}},{"id":4616057,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":29578,"kind":"person","name":"Sibold William John","position":1,"cik":"0001518611","reported_name":"Sibold William John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-09-11T20:57:12.000Z","date":"2026-09-11","kind":"sale","planned":true,"acquired":false,"shares":1539,"price":544.024,"value":837252.936,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F16","text":"These sales were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F24","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $543.27 to $544.20, inclusive."}],"balance_after":198627,"source":{"system":"sec-edgar","filing":"0001628280-26-061581","document":"wk-form4_1789160228.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1518611/000162828026061581/wk-form4_1789160228.xml","form_type":"4"}},{"id":4616056,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":29578,"kind":"person","name":"Sibold William John","position":1,"cik":"0001518611","reported_name":"Sibold William John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-09-11T20:57:12.000Z","date":"2026-09-11","kind":"sale","planned":true,"acquired":false,"shares":1202,"price":542.6032,"value":652209.0464,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F16","text":"These sales were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F23","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $542.11 to $543.02, inclusive."}],"balance_after":200166,"source":{"system":"sec-edgar","filing":"0001628280-26-061581","document":"wk-form4_1789160228.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1518611/000162828026061581/wk-form4_1789160228.xml","form_type":"4"}},{"id":4616055,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":29578,"kind":"person","name":"Sibold William John","position":1,"cik":"0001518611","reported_name":"Sibold William John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-09-11T20:57:12.000Z","date":"2026-09-11","kind":"sale","planned":true,"acquired":false,"shares":368,"price":541.6423,"value":199324.3664,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F16","text":"These sales were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F22","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $541.00 to $541.73, inclusive."}],"balance_after":201368,"source":{"system":"sec-edgar","filing":"0001628280-26-061581","document":"wk-form4_1789160228.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1518611/000162828026061581/wk-form4_1789160228.xml","form_type":"4"}},{"id":4616054,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":29578,"kind":"person","name":"Sibold William John","position":1,"cik":"0001518611","reported_name":"Sibold William John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-09-11T20:57:12.000Z","date":"2026-09-11","kind":"sale","planned":true,"acquired":false,"shares":687,"price":540.5857,"value":371382.3759,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F16","text":"These sales were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F21","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $539.97 to $540.90, inclusive."}],"balance_after":201736,"source":{"system":"sec-edgar","filing":"0001628280-26-061581","document":"wk-form4_1789160228.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1518611/000162828026061581/wk-form4_1789160228.xml","form_type":"4"}},{"id":4616053,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":29578,"kind":"person","name":"Sibold William John","position":1,"cik":"0001518611","reported_name":"Sibold William John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-09-11T20:57:12.000Z","date":"2026-09-11","kind":"sale","planned":true,"acquired":false,"shares":160,"price":537.6175,"value":86018.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F16","text":"These sales were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F20","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $537.235 to $538.00, inclusive."}],"balance_after":202423,"source":{"system":"sec-edgar","filing":"0001628280-26-061581","document":"wk-form4_1789160228.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1518611/000162828026061581/wk-form4_1789160228.xml","form_type":"4"}},{"id":4616052,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":29578,"kind":"person","name":"Sibold William John","position":1,"cik":"0001518611","reported_name":"Sibold William John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-09-11T20:57:12.000Z","date":"2026-09-11","kind":"sale","planned":true,"acquired":false,"shares":218,"price":535.9435,"value":116835.683,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F16","text":"These sales were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F19","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $535.52 to $536.02, inclusive."}],"balance_after":202583,"source":{"system":"sec-edgar","filing":"0001628280-26-061581","document":"wk-form4_1789160228.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1518611/000162828026061581/wk-form4_1789160228.xml","form_type":"4"}},{"id":4616051,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":29578,"kind":"person","name":"Sibold William John","position":1,"cik":"0001518611","reported_name":"Sibold William John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-09-11T20:57:12.000Z","date":"2026-09-11","kind":"sale","planned":true,"acquired":false,"shares":106,"price":534.063,"value":56610.678,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F16","text":"These sales were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F18","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $533.76 to $534.48, inclusive."}],"balance_after":202801,"source":{"system":"sec-edgar","filing":"0001628280-26-061581","document":"wk-form4_1789160228.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1518611/000162828026061581/wk-form4_1789160228.xml","form_type":"4"}},{"id":4616050,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":29578,"kind":"person","name":"Sibold William John","position":1,"cik":"0001518611","reported_name":"Sibold William John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-09-11T20:57:12.000Z","date":"2026-09-11","kind":"sale","planned":true,"acquired":false,"shares":60,"price":533.0913,"value":31985.478,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F16","text":"These sales were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F17","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $532.76 to $533.64, inclusive."}],"balance_after":202907,"source":{"system":"sec-edgar","filing":"0001628280-26-061581","document":"wk-form4_1789160228.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1518611/000162828026061581/wk-form4_1789160228.xml","form_type":"4"}},{"id":4616049,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":29578,"kind":"person","name":"Sibold William John","position":1,"cik":"0001518611","reported_name":"Sibold William John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-09-11T20:57:12.000Z","date":"2026-09-09","kind":"sale","planned":true,"acquired":false,"shares":160,"price":542.5475,"value":86807.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F15","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $542.42 to $542.68, inclusive."}],"balance_after":202967,"source":{"system":"sec-edgar","filing":"0001628280-26-061581","document":"wk-form4_1789160228.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1518611/000162828026061581/wk-form4_1789160228.xml","form_type":"4"}},{"id":4616048,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":29578,"kind":"person","name":"Sibold William John","position":1,"cik":"0001518611","reported_name":"Sibold William John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-09-11T20:57:12.000Z","date":"2026-09-09","kind":"sale","planned":true,"acquired":false,"shares":362,"price":541.6538,"value":196078.6756,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F14","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $541.29 to $542.27, inclusive."}],"balance_after":203127,"source":{"system":"sec-edgar","filing":"0001628280-26-061581","document":"wk-form4_1789160228.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1518611/000162828026061581/wk-form4_1789160228.xml","form_type":"4"}},{"id":4616047,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":29578,"kind":"person","name":"Sibold William John","position":1,"cik":"0001518611","reported_name":"Sibold William John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-09-11T20:57:12.000Z","date":"2026-09-09","kind":"sale","planned":true,"acquired":false,"shares":505,"price":540.1909,"value":272796.4045,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $539.86 to $540.47, inclusive."}],"balance_after":203489,"source":{"system":"sec-edgar","filing":"0001628280-26-061581","document":"wk-form4_1789160228.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1518611/000162828026061581/wk-form4_1789160228.xml","form_type":"4"}},{"id":4616046,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":29578,"kind":"person","name":"Sibold William John","position":1,"cik":"0001518611","reported_name":"Sibold William John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-09-11T20:57:12.000Z","date":"2026-09-09","kind":"sale","planned":true,"acquired":false,"shares":215,"price":539.0281,"value":115891.0415,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $538.86 to $539.83, inclusive."}],"balance_after":203994,"source":{"system":"sec-edgar","filing":"0001628280-26-061581","document":"wk-form4_1789160228.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1518611/000162828026061581/wk-form4_1789160228.xml","form_type":"4"}},{"id":4616045,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":29578,"kind":"person","name":"Sibold William John","position":1,"cik":"0001518611","reported_name":"Sibold William John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-09-11T20:57:12.000Z","date":"2026-09-09","kind":"sale","planned":true,"acquired":false,"shares":520,"price":538.2971,"value":279914.492,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $537.70 to $538.65, inclusive."}],"balance_after":204209,"source":{"system":"sec-edgar","filing":"0001628280-26-061581","document":"wk-form4_1789160228.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1518611/000162828026061581/wk-form4_1789160228.xml","form_type":"4"}},{"id":4616044,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":29578,"kind":"person","name":"Sibold William John","position":1,"cik":"0001518611","reported_name":"Sibold William John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-09-11T20:57:12.000Z","date":"2026-09-09","kind":"sale","planned":true,"acquired":false,"shares":640,"price":537.1738,"value":343791.232,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $536.64 to $537.56, inclusive."}],"balance_after":204729,"source":{"system":"sec-edgar","filing":"0001628280-26-061581","document":"wk-form4_1789160228.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1518611/000162828026061581/wk-form4_1789160228.xml","form_type":"4"}},{"id":4616043,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":29578,"kind":"person","name":"Sibold William John","position":1,"cik":"0001518611","reported_name":"Sibold William John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-09-11T20:57:12.000Z","date":"2026-09-09","kind":"sale","planned":true,"acquired":false,"shares":1040,"price":536.1123,"value":557556.792,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $535.64 to $536.45, inclusive."}],"balance_after":205369,"source":{"system":"sec-edgar","filing":"0001628280-26-061581","document":"wk-form4_1789160228.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1518611/000162828026061581/wk-form4_1789160228.xml","form_type":"4"}},{"id":4616042,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":29578,"kind":"person","name":"Sibold William John","position":1,"cik":"0001518611","reported_name":"Sibold William John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-09-11T20:57:12.000Z","date":"2026-09-09","kind":"sale","planned":true,"acquired":false,"shares":644,"price":535.2719,"value":344715.1036,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $534.63 to $535.62, inclusive."}],"balance_after":206409,"source":{"system":"sec-edgar","filing":"0001628280-26-061581","document":"wk-form4_1789160228.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1518611/000162828026061581/wk-form4_1789160228.xml","form_type":"4"}},{"id":4616041,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":29578,"kind":"person","name":"Sibold William John","position":1,"cik":"0001518611","reported_name":"Sibold William John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-09-11T20:57:12.000Z","date":"2026-09-09","kind":"sale","planned":true,"acquired":false,"shares":396,"price":534.1964,"value":211541.7744,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $533.58 to $534.57, inclusive."}],"balance_after":207053,"source":{"system":"sec-edgar","filing":"0001628280-26-061581","document":"wk-form4_1789160228.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1518611/000162828026061581/wk-form4_1789160228.xml","form_type":"4"}},{"id":4616040,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":29578,"kind":"person","name":"Sibold William John","position":1,"cik":"0001518611","reported_name":"Sibold William John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-09-11T20:57:12.000Z","date":"2026-09-09","kind":"sale","planned":true,"acquired":false,"shares":512,"price":533.0932,"value":272943.7184,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $532.57 to $533.29, inclusive."}],"balance_after":207449,"source":{"system":"sec-edgar","filing":"0001628280-26-061581","document":"wk-form4_1789160228.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1518611/000162828026061581/wk-form4_1789160228.xml","form_type":"4"}},{"id":4616039,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":29578,"kind":"person","name":"Sibold William John","position":1,"cik":"0001518611","reported_name":"Sibold William John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-09-11T20:57:12.000Z","date":"2026-09-09","kind":"sale","planned":true,"acquired":false,"shares":368,"price":531.9897,"value":195772.2096,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $531.57 to $532.28, inclusive."}],"balance_after":207961,"source":{"system":"sec-edgar","filing":"0001628280-26-061581","document":"wk-form4_1789160228.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1518611/000162828026061581/wk-form4_1789160228.xml","form_type":"4"}},{"id":4616038,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":29578,"kind":"person","name":"Sibold William John","position":1,"cik":"0001518611","reported_name":"Sibold William John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-09-11T20:57:12.000Z","date":"2026-09-09","kind":"sale","planned":true,"acquired":false,"shares":522,"price":530.2311,"value":276780.6342,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $529.64 to $530.48, inclusive."}],"balance_after":208329,"source":{"system":"sec-edgar","filing":"0001628280-26-061581","document":"wk-form4_1789160228.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1518611/000162828026061581/wk-form4_1789160228.xml","form_type":"4"}},{"id":4616037,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":29578,"kind":"person","name":"Sibold William John","position":1,"cik":"0001518611","reported_name":"Sibold William John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-09-11T20:57:12.000Z","date":"2026-09-09","kind":"sale","planned":true,"acquired":false,"shares":347,"price":529.2671,"value":183655.6837,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $528.54 to $529.51, inclusive."}],"balance_after":208851,"source":{"system":"sec-edgar","filing":"0001628280-26-061581","document":"wk-form4_1789160228.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1518611/000162828026061581/wk-form4_1789160228.xml","form_type":"4"}},{"id":4616036,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":29578,"kind":"person","name":"Sibold William John","position":1,"cik":"0001518611","reported_name":"Sibold William John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-09-11T20:57:12.000Z","date":"2026-09-09","kind":"sale","planned":true,"acquired":false,"shares":131,"price":527.8783,"value":69152.0573,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $527.49 to $528.27, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below."}],"balance_after":209198,"source":{"system":"sec-edgar","filing":"0001628280-26-061581","document":"wk-form4_1789160228.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1518611/000162828026061581/wk-form4_1789160228.xml","form_type":"4"}},{"id":705933,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":29578,"kind":"person","name":"Sibold William John","position":1,"cik":"0001518611","reported_name":"Sibold William John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Performance Restricted Stock Units","published_at":"2026-07-21T01:16:52.000Z","date":"2026-07-17","kind":"exercise","planned":false,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F12","text":"On September 11, 2023, the Reporting Person was granted a one-time sign-on award of Performance Restricted Stock Units with a target award of 50,000 shares of common stock that could be earned upon the achievement of significant sustained stock price appreciation hurdles over a five-year period. The Reporting Person was eligible to earn up to 300% of the target award. Following the achievement of the first hurdle in February 2025, the second hurdle in December 2025 and the third and final hurdle reported on this line, all performance hurdles have been achieved. See the Issuer's Schedule 14A filed with the Securities and Exchange Commission on April 29, 2024 for additional information about the Performance Restricted Stock Units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"On September 11, 2023, the Reporting Person was granted a one-time sign-on award of Performance Restricted Stock Units with a target award of 50,000 shares of common stock that could be earned upon the achievement of significant sustained stock price appreciation hurdles over a five-year period. The Reporting Person was eligible to earn up to 300% of the target award. Following the achievement of the first hurdle in February 2025, the second hurdle in December 2025 and the third and final hurdle reported on this line, all performance hurdles have been achieved. See the Issuer's Schedule 14A filed with the Securities and Exchange Commission on April 29, 2024 for additional information about the Performance Restricted Stock Units."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F12","text":"On September 11, 2023, the Reporting Person was granted a one-time sign-on award of Performance Restricted Stock Units with a target award of 50,000 shares of common stock that could be earned upon the achievement of significant sustained stock price appreciation hurdles over a five-year period. The Reporting Person was eligible to earn up to 300% of the target award. Following the achievement of the first hurdle in February 2025, the second hurdle in December 2025 and the third and final hurdle reported on this line, all performance hurdles have been achieved. See the Issuer's Schedule 14A filed with the Securities and Exchange Commission on April 29, 2024 for additional information about the Performance Restricted Stock Units."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001628280-26-048919","document":"wk-form4_1784596610.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828026048919/wk-form4_1784596610.xml","form_type":"4"}},{"id":705932,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":29578,"kind":"person","name":"Sibold William John","position":1,"cik":"0001518611","reported_name":"Sibold William John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-07-21T01:16:52.000Z","date":"2026-07-20","kind":"sale","planned":false,"acquired":false,"shares":280,"price":555.05,"value":155414.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported on this line represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover certain tax withholding obligations in connection with the Reporting Person earning 50,000 shares of common stock as described in Footnote 1 above. This sale was automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $555.00 to $555.10, inclusive."}],"balance_after":209329,"source":{"system":"sec-edgar","filing":"0001628280-26-048919","document":"wk-form4_1784596610.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828026048919/wk-form4_1784596610.xml","form_type":"4"}},{"id":705931,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":29578,"kind":"person","name":"Sibold William John","position":1,"cik":"0001518611","reported_name":"Sibold William John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-07-21T01:16:52.000Z","date":"2026-07-20","kind":"sale","planned":false,"acquired":false,"shares":1,"price":550.72,"value":550.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported on this line represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover certain tax withholding obligations in connection with the Reporting Person earning 50,000 shares of common stock as described in Footnote 1 above. This sale was automatic and not at the discretion of the Reporting Person."}],"balance_after":209609,"source":{"system":"sec-edgar","filing":"0001628280-26-048919","document":"wk-form4_1784596610.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828026048919/wk-form4_1784596610.xml","form_type":"4"}},{"id":705930,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":29578,"kind":"person","name":"Sibold William John","position":1,"cik":"0001518611","reported_name":"Sibold William John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-07-21T01:16:52.000Z","date":"2026-07-20","kind":"sale","planned":false,"acquired":false,"shares":153,"price":550.0138,"value":84152.1114,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported on this line represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover certain tax withholding obligations in connection with the Reporting Person earning 50,000 shares of common stock as described in Footnote 1 above. This sale was automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $549.70 to $550.24, inclusive."}],"balance_after":209610,"source":{"system":"sec-edgar","filing":"0001628280-26-048919","document":"wk-form4_1784596610.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828026048919/wk-form4_1784596610.xml","form_type":"4"}},{"id":705929,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":29578,"kind":"person","name":"Sibold William John","position":1,"cik":"0001518611","reported_name":"Sibold William John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-07-21T01:16:52.000Z","date":"2026-07-20","kind":"sale","planned":false,"acquired":false,"shares":47,"price":548.8719,"value":25796.9793,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported on this line represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover certain tax withholding obligations in connection with the Reporting Person earning 50,000 shares of common stock as described in Footnote 1 above. This sale was automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $548.42 to $549.39, inclusive."}],"balance_after":209763,"source":{"system":"sec-edgar","filing":"0001628280-26-048919","document":"wk-form4_1784596610.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828026048919/wk-form4_1784596610.xml","form_type":"4"}},{"id":705928,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":29578,"kind":"person","name":"Sibold William John","position":1,"cik":"0001518611","reported_name":"Sibold William John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-07-21T01:16:52.000Z","date":"2026-07-20","kind":"sale","planned":false,"acquired":false,"shares":680,"price":547.698,"value":372434.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported on this line represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover certain tax withholding obligations in connection with the Reporting Person earning 50,000 shares of common stock as described in Footnote 1 above. This sale was automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $547.40 to $548.29, inclusive."}],"balance_after":209810,"source":{"system":"sec-edgar","filing":"0001628280-26-048919","document":"wk-form4_1784596610.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828026048919/wk-form4_1784596610.xml","form_type":"4"}},{"id":705927,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":29578,"kind":"person","name":"Sibold William John","position":1,"cik":"0001518611","reported_name":"Sibold William John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-07-21T01:16:52.000Z","date":"2026-07-20","kind":"sale","planned":false,"acquired":false,"shares":269,"price":547.0788,"value":147164.1972,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported on this line represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover certain tax withholding obligations in connection with the Reporting Person earning 50,000 shares of common stock as described in Footnote 1 above. This sale was automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $546.37 to $547.35, inclusive."}],"balance_after":210490,"source":{"system":"sec-edgar","filing":"0001628280-26-048919","document":"wk-form4_1784596610.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828026048919/wk-form4_1784596610.xml","form_type":"4"}},{"id":705926,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":29578,"kind":"person","name":"Sibold William John","position":1,"cik":"0001518611","reported_name":"Sibold William John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-07-21T01:16:52.000Z","date":"2026-07-20","kind":"sale","planned":false,"acquired":false,"shares":275,"price":545.7092,"value":150070.03,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported on this line represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover certain tax withholding obligations in connection with the Reporting Person earning 50,000 shares of common stock as described in Footnote 1 above. This sale was automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $545.31 to $546.29, inclusive."}],"balance_after":210759,"source":{"system":"sec-edgar","filing":"0001628280-26-048919","document":"wk-form4_1784596610.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828026048919/wk-form4_1784596610.xml","form_type":"4"}},{"id":705925,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":29578,"kind":"person","name":"Sibold William John","position":1,"cik":"0001518611","reported_name":"Sibold William John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-07-21T01:16:52.000Z","date":"2026-07-20","kind":"sale","planned":false,"acquired":false,"shares":545,"price":544.714,"value":296869.13,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported on this line represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover certain tax withholding obligations in connection with the Reporting Person earning 50,000 shares of common stock as described in Footnote 1 above. This sale was automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $544.31 to $545.28, inclusive."}],"balance_after":211034,"source":{"system":"sec-edgar","filing":"0001628280-26-048919","document":"wk-form4_1784596610.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828026048919/wk-form4_1784596610.xml","form_type":"4"}},{"id":705924,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":29578,"kind":"person","name":"Sibold William John","position":1,"cik":"0001518611","reported_name":"Sibold William John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-07-21T01:16:52.000Z","date":"2026-07-20","kind":"sale","planned":false,"acquired":false,"shares":110,"price":543.7929,"value":59817.219,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported on this line represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover certain tax withholding obligations in connection with the Reporting Person earning 50,000 shares of common stock as described in Footnote 1 above. This sale was automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $543.26 to $544.25, inclusive."}],"balance_after":211579,"source":{"system":"sec-edgar","filing":"0001628280-26-048919","document":"wk-form4_1784596610.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828026048919/wk-form4_1784596610.xml","form_type":"4"}},{"id":705923,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":29578,"kind":"person","name":"Sibold William John","position":1,"cik":"0001518611","reported_name":"Sibold William John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-07-21T01:16:52.000Z","date":"2026-07-20","kind":"sale","planned":false,"acquired":false,"shares":140,"price":542.7459,"value":75984.426,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported on this line represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover certain tax withholding obligations in connection with the Reporting Person earning 50,000 shares of common stock as described in Footnote 1 above. This sale was automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $542.22 to $543.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below."}],"balance_after":211689,"source":{"system":"sec-edgar","filing":"0001628280-26-048919","document":"wk-form4_1784596610.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828026048919/wk-form4_1784596610.xml","form_type":"4"}},{"id":705922,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":29578,"kind":"person","name":"Sibold William John","position":1,"cik":"0001518611","reported_name":"Sibold William John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-07-21T01:16:52.000Z","date":"2026-07-17","kind":"exercise","planned":false,"acquired":true,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 17, 2026, the Reporting Person earned 50,000 shares of common stock following the achievement of the performance and service conditions of the Performance Restricted Stock Units described in Footnote 12. Pursuant to the terms of the award, certain of these shares were sold to cover certain tax withholding obligations as described in Footnote 2 below. The Issuer is irrevocably obligated to issue the remaining shares to the Reporting Person on September 8, 2029, the sixth anniversary of the commencement of his employment with the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 17, 2026, the Reporting Person earned 50,000 shares of common stock following the achievement of the performance and service conditions of the Performance Restricted Stock Units described in Footnote 12. Pursuant to the terms of the award, certain of these shares were sold to cover certain tax withholding obligations as described in Footnote 2 below. The Issuer is irrevocably obligated to issue the remaining shares to the Reporting Person on September 8, 2029, the sixth anniversary of the commencement of his employment with the Issuer."}],"balance_after":211829,"source":{"system":"sec-edgar","filing":"0001628280-26-048919","document":"wk-form4_1784596610.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828026048919/wk-form4_1784596610.xml","form_type":"4"}},{"id":856470,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":29578,"kind":"person","name":"Sibold William John","position":1,"cik":"0001518611","reported_name":"Sibold William John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-06T23:49:18.000Z","date":"2026-03-04","kind":"grant","planned":false,"acquired":true,"shares":18743,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests as to 25% of the shares on the first anniversary of the date of grant (March 4, 2027) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date."}],"balance_after":18743,"derivative":{"exercise_price":434.8,"expiration_date":"2036-03-04","underlying":"Common Stock","underlying_shares":18743},"source":{"system":"sec-edgar","filing":"0001628280-26-015769","document":"wk-form4_1772840956.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828026015769/wk-form4_1772840956.xml","form_type":"4"}},{"id":856469,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":29578,"kind":"person","name":"Sibold William John","position":1,"cik":"0001518611","reported_name":"Sibold William John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-03-06T23:49:18.000Z","date":"2026-03-06","kind":"sale","planned":false,"acquired":false,"shares":1663,"price":431.94,"value":718316.22,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person."}],"balance_after":161829,"source":{"system":"sec-edgar","filing":"0001628280-26-015769","document":"wk-form4_1772840956.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828026015769/wk-form4_1772840956.xml","form_type":"4"}},{"id":856468,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":29578,"kind":"person","name":"Sibold William John","position":1,"cik":"0001518611","reported_name":"Sibold William John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-03-06T23:49:18.000Z","date":"2026-03-04","kind":"grant","planned":false,"acquired":true,"shares":14995,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a grant of restricted stock units, which vest as to 25% of the shares on each of March 4, 2027, March 4, 2028, March 4, 2029 and March 4, 2030, provided the Reporting Person continues in service with the Issuer on each such date."}],"balance_after":163492,"source":{"system":"sec-edgar","filing":"0001628280-26-015769","document":"wk-form4_1772840956.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828026015769/wk-form4_1772840956.xml","form_type":"4"}},{"id":931344,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":29578,"kind":"person","name":"Sibold William John","position":1,"cik":"0001518611","reported_name":"Sibold William John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-01-26T22:14:56.000Z","date":"2026-01-26","kind":"sale","planned":false,"acquired":false,"shares":1577,"price":492.42,"value":776546.34,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person."}],"balance_after":148497,"source":{"system":"sec-edgar","filing":"0001628280-26-003468","document":"wk-form4_1769465694.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828026003468/wk-form4_1769465694.xml","form_type":"4"}},{"id":980553,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":29578,"kind":"person","name":"Sibold William John","position":1,"cik":"0001518611","reported_name":"Sibold William John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Performance Restricted Stock Units","published_at":"2025-12-04T22:26:58.000Z","date":"2025-12-03","kind":"exercise","planned":false,"acquired":false,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"On September 11, 2023, the Reporting Person was granted a one-time sign-on award of Performance Restricted Stock Units with a target award of 50,000 shares of common stock that can be earned upon the achievement of significant sustained stock price appreciation hurdles over a five-year period. The Reporting Person can earn up to 300% of the target award.  Following the achievement of the first hurdle in February 2025 and the second hurdle reported on this line, the Reporting Person is eligible to earn an additional 50,000 shares upon the achievement of the final performance hurdle. See the Issuer's Schedule 14A filed with the Securities and Exchange Commission on April 29, 2024 for additional information about the Performance Restricted Stock Units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On September 11, 2023, the Reporting Person was granted a one-time sign-on award of Performance Restricted Stock Units with a target award of 50,000 shares of common stock that can be earned upon the achievement of significant sustained stock price appreciation hurdles over a five-year period. The Reporting Person can earn up to 300% of the target award.  Following the achievement of the first hurdle in February 2025 and the second hurdle reported on this line, the Reporting Person is eligible to earn an additional 50,000 shares upon the achievement of the final performance hurdle. See the Issuer's Schedule 14A filed with the Securities and Exchange Commission on April 29, 2024 for additional information about the Performance Restricted Stock Units."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On September 11, 2023, the Reporting Person was granted a one-time sign-on award of Performance Restricted Stock Units with a target award of 50,000 shares of common stock that can be earned upon the achievement of significant sustained stock price appreciation hurdles over a five-year period. The Reporting Person can earn up to 300% of the target award.  Following the achievement of the first hurdle in February 2025 and the second hurdle reported on this line, the Reporting Person is eligible to earn an additional 50,000 shares upon the achievement of the final performance hurdle. See the Issuer's Schedule 14A filed with the Securities and Exchange Commission on April 29, 2024 for additional information about the Performance Restricted Stock Units."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On September 11, 2023, the Reporting Person was granted a one-time sign-on award of Performance Restricted Stock Units with a target award of 50,000 shares of common stock that can be earned upon the achievement of significant sustained stock price appreciation hurdles over a five-year period. The Reporting Person can earn up to 300% of the target award.  Following the achievement of the first hurdle in February 2025 and the second hurdle reported on this line, the Reporting Person is eligible to earn an additional 50,000 shares upon the achievement of the final performance hurdle. See the Issuer's Schedule 14A filed with the Securities and Exchange Commission on April 29, 2024 for additional information about the Performance Restricted Stock Units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"On September 11, 2023, the Reporting Person was granted a one-time sign-on award of Performance Restricted Stock Units with a target award of 50,000 shares of common stock that can be earned upon the achievement of significant sustained stock price appreciation hurdles over a five-year period. The Reporting Person can earn up to 300% of the target award.  Following the achievement of the first hurdle in February 2025 and the second hurdle reported on this line, the Reporting Person is eligible to earn an additional 50,000 shares upon the achievement of the final performance hurdle. See the Issuer's Schedule 14A filed with the Securities and Exchange Commission on April 29, 2024 for additional information about the Performance Restricted Stock Units."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001628280-25-055430","document":"wk-form4_1764887216.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025055430/wk-form4_1764887216.xml","form_type":"4"}},{"id":980552,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":29578,"kind":"person","name":"Sibold William John","position":1,"cik":"0001518611","reported_name":"Sibold William John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-12-04T22:26:58.000Z","date":"2025-12-04","kind":"sale","planned":false,"acquired":false,"shares":2400,"price":575.34,"value":1380816.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported on this line represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover certain tax withholding obligations in connection with the Reporting Person earning 50,000 shares of common stock as described in Footnote 1 above. This sale was automatic and not at the discretion of the Reporting Person."}],"balance_after":150074,"source":{"system":"sec-edgar","filing":"0001628280-25-055430","document":"wk-form4_1764887216.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025055430/wk-form4_1764887216.xml","form_type":"4"}},{"id":980551,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":29578,"kind":"person","name":"Sibold William John","position":1,"cik":"0001518611","reported_name":"Sibold William John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-12-04T22:26:58.000Z","date":"2025-12-03","kind":"exercise","planned":false,"acquired":true,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 3, 2025, the Reporting Person earned 50,000 shares of common stock following the achievement of the performance and service conditions of the Performance Restricted Stock Units described in Footnote 3. Pursuant to the terms of the award, certain of these shares were sold to cover certain tax withholding obligations as described in Footnote 2 below. The Issuer is irrevocably obligated to issue the remaining shares to the Reporting Person on September 8, 2028, the fifth anniversary of the commencement of his employment with the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 3, 2025, the Reporting Person earned 50,000 shares of common stock following the achievement of the performance and service conditions of the Performance Restricted Stock Units described in Footnote 3. Pursuant to the terms of the award, certain of these shares were sold to cover certain tax withholding obligations as described in Footnote 2 below. The Issuer is irrevocably obligated to issue the remaining shares to the Reporting Person on September 8, 2028, the fifth anniversary of the commencement of his employment with the Issuer."}],"balance_after":152474,"source":{"system":"sec-edgar","filing":"0001628280-25-055430","document":"wk-form4_1764887216.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025055430/wk-form4_1764887216.xml","form_type":"4"}},{"id":1045035,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":29578,"kind":"person","name":"Sibold William John","position":1,"cik":"0001518611","reported_name":"Sibold William John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-09-10T01:07:34.000Z","date":"2025-09-09","kind":"sale","planned":false,"acquired":false,"shares":7279,"price":445.63,"value":3243740.77,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units."}],"balance_after":102474,"source":{"system":"sec-edgar","filing":"0001518611-25-000009","document":"wk-form4_1757466450.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000151861125000009/wk-form4_1757466450.xml","form_type":"4"}},{"id":1059493,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":29578,"kind":"person","name":"Sibold William John","position":1,"cik":"0001518611","reported_name":"Sibold William John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-08-21T21:44:27.000Z","date":"2025-08-21","kind":"sale","planned":true,"acquired":false,"shares":1131,"price":401.0003,"value":453531.3393,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $401.00 to $401.01, inclusive."}],"balance_after":109753,"source":{"system":"sec-edgar","filing":"0001518611-25-000007","document":"wk-form4_1755812664.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000151861125000007/wk-form4_1755812664.xml","form_type":"4"}},{"id":1059492,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":29578,"kind":"person","name":"Sibold William John","position":1,"cik":"0001518611","reported_name":"Sibold William John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-08-21T21:44:27.000Z","date":"2025-08-21","kind":"sale","planned":true,"acquired":false,"shares":6485,"price":400.0347,"value":2594225.0295,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $400.00 to $400.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnote below."}],"balance_after":110884,"source":{"system":"sec-edgar","filing":"0001518611-25-000007","document":"wk-form4_1755812664.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000151861125000007/wk-form4_1755812664.xml","form_type":"4"}},{"id":1217923,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":29578,"kind":"person","name":"Sibold William John","position":1,"cik":"0001518611","reported_name":"Sibold William John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-07T22:47:56.000Z","date":"2025-03-05","kind":"grant","planned":false,"acquired":true,"shares":22009,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests as to 25% of the shares on the first anniversary of the date of grant (March 5, 2026) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date."}],"balance_after":22009,"derivative":{"exercise_price":347.28,"expiration_date":"2035-03-05","underlying":"Common Stock","underlying_shares":22009},"source":{"system":"sec-edgar","filing":"0001628280-25-011410","document":"wk-form4_1741387671.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025011410/wk-form4_1741387671.xml","form_type":"4"}},{"id":1217922,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":29578,"kind":"person","name":"Sibold William John","position":1,"cik":"0001518611","reported_name":"Sibold William John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-03-07T22:47:56.000Z","date":"2025-03-05","kind":"grant","planned":false,"acquired":true,"shares":13066,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a grant of restricted stock units, which vest as to 25% of the shares on each of March 5, 2026, March 5, 2027, March 5, 2028 and March 5, 2029, provided the Reporting Person continues in service with the Issuer on each such date."}],"balance_after":117369,"source":{"system":"sec-edgar","filing":"0001628280-25-011410","document":"wk-form4_1741387671.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025011410/wk-form4_1741387671.xml","form_type":"4"}},{"id":1238962,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":29578,"kind":"person","name":"Sibold William John","position":1,"cik":"0001518611","reported_name":"Sibold William John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Performance Restricted Stock Units","published_at":"2025-02-28T21:36:27.000Z","date":"2025-02-27","kind":"exercise","planned":false,"acquired":false,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On September 11, 2023, the Reporting Person was granted a one-time sign-on award of performance-based restricted stock units (PSUs) with a target award of 50,000 shares of common stock that can be earned upon the achievement of significant sustained stock price appreciation hurdles over a five-year period. The Reporting Person can earn up to 300% of the target award and is eligible to earn up to an additional 100,000 shares upon the achievement of sustained stock price appreciation hurdles. See the Issuer's Schedule 14A filed with the Securities and Exchange Commission on April 29, 2024 for additional information about the PSUs."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On September 11, 2023, the Reporting Person was granted a one-time sign-on award of performance-based restricted stock units (PSUs) with a target award of 50,000 shares of common stock that can be earned upon the achievement of significant sustained stock price appreciation hurdles over a five-year period. The Reporting Person can earn up to 300% of the target award and is eligible to earn up to an additional 100,000 shares upon the achievement of sustained stock price appreciation hurdles. See the Issuer's Schedule 14A filed with the Securities and Exchange Commission on April 29, 2024 for additional information about the PSUs."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On September 11, 2023, the Reporting Person was granted a one-time sign-on award of performance-based restricted stock units (PSUs) with a target award of 50,000 shares of common stock that can be earned upon the achievement of significant sustained stock price appreciation hurdles over a five-year period. The Reporting Person can earn up to 300% of the target award and is eligible to earn up to an additional 100,000 shares upon the achievement of sustained stock price appreciation hurdles. See the Issuer's Schedule 14A filed with the Securities and Exchange Commission on April 29, 2024 for additional information about the PSUs."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On September 11, 2023, the Reporting Person was granted a one-time sign-on award of performance-based restricted stock units (PSUs) with a target award of 50,000 shares of common stock that can be earned upon the achievement of significant sustained stock price appreciation hurdles over a five-year period. The Reporting Person can earn up to 300% of the target award and is eligible to earn up to an additional 100,000 shares upon the achievement of sustained stock price appreciation hurdles. See the Issuer's Schedule 14A filed with the Securities and Exchange Commission on April 29, 2024 for additional information about the PSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On September 11, 2023, the Reporting Person was granted a one-time sign-on award of performance-based restricted stock units (PSUs) with a target award of 50,000 shares of common stock that can be earned upon the achievement of significant sustained stock price appreciation hurdles over a five-year period. The Reporting Person can earn up to 300% of the target award and is eligible to earn up to an additional 100,000 shares upon the achievement of sustained stock price appreciation hurdles. See the Issuer's Schedule 14A filed with the Securities and Exchange Commission on April 29, 2024 for additional information about the PSUs."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001628280-25-009091","document":"wk-form4_1740778579.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025009091/wk-form4_1740778579.xml","form_type":"4"}},{"id":1238961,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":29578,"kind":"person","name":"Sibold William John","position":1,"cik":"0001518611","reported_name":"Sibold William John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-02-28T21:36:27.000Z","date":"2025-02-27","kind":"exercise","planned":false,"acquired":true,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 27, 2025, the Reporting Person earned 50,000 shares of common stock following the achievement of the performance and service conditions of the Performance Restricted Stock Units described in Footnote 2. Although the Issuer is irrevocably obligated to issue these shares to the Reporting Person, these shares will settle and be delivered to the Reporting Person on September 8, 2027, the fourth anniversary of the commencement of his employment with the Issuer."}],"balance_after":104303,"source":{"system":"sec-edgar","filing":"0001628280-25-009091","document":"wk-form4_1740778579.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025009091/wk-form4_1740778579.xml","form_type":"4"}},{"id":1294655,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":29578,"kind":"person","name":"Sibold William John","position":1,"cik":"0001518611","reported_name":"Sibold William John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-01-27T22:12:21.000Z","date":"2025-01-24","kind":"sale","planned":false,"acquired":false,"shares":1584,"price":335.24,"value":531020.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person."}],"balance_after":54303,"source":{"system":"sec-edgar","filing":"0001628280-25-002666","document":"wk-form4_1738015934.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828025002666/wk-form4_1738015934.xml","form_type":"4"}},{"id":1410011,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":29578,"kind":"person","name":"Sibold William John","position":1,"cik":"0001518611","reported_name":"Sibold William John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-09-12T01:51:22.000Z","date":"2024-09-09","kind":"sale","planned":false,"acquired":false,"shares":6363,"price":243.83,"value":1551490.29,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."}],"balance_after":55887,"source":{"system":"sec-edgar","filing":"0000950170-24-105650","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000095017024105650/ownership.xml","form_type":"4"}},{"id":1671164,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":29578,"kind":"person","name":"Sibold William John","position":1,"cik":"0001518611","reported_name":"Sibold William John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Market Stock Unit","published_at":"2024-01-25T20:24:16.000Z","date":"2024-01-23","kind":"grant","planned":false,"acquired":true,"shares":12250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each market stock unit, which is performance-based, represents the contingent right to receive one share of common stock. The amount reported represents the target number of shares which may be issued upon vesting. The market stock units will vest upon certification concerning the Company's stock price performance measured against biotechnology stock index companies for the entire performance period ending December 31, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each market stock unit, which is performance-based, represents the contingent right to receive one share of common stock. The amount reported represents the target number of shares which may be issued upon vesting. The market stock units will vest upon certification concerning the Company's stock price performance measured against biotechnology stock index companies for the entire performance period ending December 31, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each market stock unit, which is performance-based, represents the contingent right to receive one share of common stock. The amount reported represents the target number of shares which may be issued upon vesting. The market stock units will vest upon certification concerning the Company's stock price performance measured against biotechnology stock index companies for the entire performance period ending December 31, 2026."}],"balance_after":12250,"derivative":{"underlying":"Common Stock","underlying_shares":12250},"source":{"system":"sec-edgar","filing":"0000950170-24-007347","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000095017024007347/ownership.xml","form_type":"4"}},{"id":1671163,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":29578,"kind":"person","name":"Sibold William John","position":1,"cik":"0001518611","reported_name":"Sibold William John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-25T20:24:16.000Z","date":"2024-01-23","kind":"grant","planned":false,"acquired":true,"shares":18459,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests as to 25% of the shares on the first anniversary of the date of grant (January 23, 2025) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date."}],"balance_after":18459,"derivative":{"exercise_price":229,"expiration_date":"2031-01-23","underlying":"Common Stock","underlying_shares":18459},"source":{"system":"sec-edgar","filing":"0000950170-24-007347","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000095017024007347/ownership.xml","form_type":"4"}},{"id":1671162,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":29578,"kind":"person","name":"Sibold William John","position":1,"cik":"0001518611","reported_name":"Sibold William John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-01-25T20:24:16.000Z","date":"2024-01-23","kind":"grant","planned":false,"acquired":true,"shares":12250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a grant of restricted stock units, which vest as to 25% of the shares on each of January 23, 2025, January 23, 2026, January 23, 2027 and January 23, 2028, provided the Reporting Person continues in service with the Issuer on each such date."}],"balance_after":62250,"source":{"system":"sec-edgar","filing":"0000950170-24-007347","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000095017024007347/ownership.xml","form_type":"4"}},{"id":1782300,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":29578,"kind":"person","name":"Sibold William John","position":1,"cik":"0001518611","reported_name":"Sibold William John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Performance Restricted Stock Units","published_at":"2023-09-13T20:41:14.000Z","date":"2023-09-11","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Represents a grant of performance-based restricted stock units, which represent the contingent right to receive a number of shares of the Issuer's common stock that is between 0% and 300% of the target amount of units, depending on the Issuer's achievement of significant sustained stock price appreciation hurdles over a five-year period and which may settle on the 4th, 5th and 6th anniversaries of the grant date, depending on the date of vesting and performance level achieved. The number of shares of common stock reported assumes a target that corresponds to a 100% payout level."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents a grant of performance-based restricted stock units, which represent the contingent right to receive a number of shares of the Issuer's common stock that is between 0% and 300% of the target amount of units, depending on the Issuer's achievement of significant sustained stock price appreciation hurdles over a five-year period and which may settle on the 4th, 5th and 6th anniversaries of the grant date, depending on the date of vesting and performance level achieved. The number of shares of common stock reported assumes a target that corresponds to a 100% payout level."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents a grant of performance-based restricted stock units, which represent the contingent right to receive a number of shares of the Issuer's common stock that is between 0% and 300% of the target amount of units, depending on the Issuer's achievement of significant sustained stock price appreciation hurdles over a five-year period and which may settle on the 4th, 5th and 6th anniversaries of the grant date, depending on the date of vesting and performance level achieved. The number of shares of common stock reported assumes a target that corresponds to a 100% payout level."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Represents a grant of performance-based restricted stock units, which represent the contingent right to receive a number of shares of the Issuer's common stock that is between 0% and 300% of the target amount of units, depending on the Issuer's achievement of significant sustained stock price appreciation hurdles over a five-year period and which may settle on the 4th, 5th and 6th anniversaries of the grant date, depending on the date of vesting and performance level achieved. The number of shares of common stock reported assumes a target that corresponds to a 100% payout level."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Represents a grant of performance-based restricted stock units, which represent the contingent right to receive a number of shares of the Issuer's common stock that is between 0% and 300% of the target amount of units, depending on the Issuer's achievement of significant sustained stock price appreciation hurdles over a five-year period and which may settle on the 4th, 5th and 6th anniversaries of the grant date, depending on the date of vesting and performance level achieved. The number of shares of common stock reported assumes a target that corresponds to a 100% payout level."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Represents a grant of performance-based restricted stock units, which represent the contingent right to receive a number of shares of the Issuer's common stock that is between 0% and 300% of the target amount of units, depending on the Issuer's achievement of significant sustained stock price appreciation hurdles over a five-year period and which may settle on the 4th, 5th and 6th anniversaries of the grant date, depending on the date of vesting and performance level achieved. The number of shares of common stock reported assumes a target that corresponds to a 100% payout level."}],"balance_after":50000,"derivative":{"underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000950170-23-047950","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000095017023047950/ownership.xml","form_type":"4"}},{"id":1782299,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":29578,"kind":"person","name":"Sibold William John","position":1,"cik":"0001518611","reported_name":"Sibold William John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-09-13T20:41:14.000Z","date":"2023-09-11","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a grant of restricted stock units, which vest as to 25% of the shares on each of September 8, 2024, September 8, 2025, September 8, 2026 and September 8, 2027, provided the Reporting Person continues in service with the Issuer on each such date."}],"balance_after":50000,"source":{"system":"sec-edgar","filing":"0000950170-23-047950","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000095017023047950/ownership.xml","form_type":"4"}}]}